Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19712047 | 0.88 | S1PR1 (0.33) | NPC1RAB9AACSS2KCNH2SMN1; SMN2 | |
| SCHEMBL29359764 | 0.88 | S1PR1 (0.33) | NPC1RAB9AACSS2KCNH2SMN1; SMN2 | |
| SCHEMBL20100093 | 0.87 | KDM4E (0.36) | HSD17B10NPC1RAB9ACA12CA9 | |
| SCHEMBL31207155 | 0.87 | TRPA1 (0.36) | KCNH2 | |
| SCHEMBL21805957 | 0.87 | TRPA1 (0.36) | KCNH2 | |
| SCHEMBL20393708 | 0.84 | PTGS2 (0.40) | HSD17B10NPC1RAB9ACA12CA9 | |
| SCHEMBL20393874 | 0.83 | LMNA (0.35) | NPC1RAB9ACA12CA9ACSS2 | |
| SCHEMBL18131796 | 0.82 | NPC1 (0.42) | HSD17B10NPC1RAB9AGRIN1GRIN2A | |
| SCHEMBL18131807 | 0.82 | HSD17B10 (0.33) | HSD17B10NPC1RAB9ARECQLGRIN1 | |
| SCHEMBL20393766 | 0.82 | KDM4E (0.42) | HSD17B10NPC1RAB9ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280716-B1 | IMIDAZO[1,2-A]PYRIDIN-2-YL DERIVATIVES AS PESTICIDES AND INTERMEDIATES THEREOF | BAYER CROPSCIENCE AG (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-10188108-B2 | Fused bicyclic heterocycle derivatives as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180116222-A1 | FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| WO-2016162318-A1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTS AND INTERMEDIATE PRODUCT | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188108-B2 | Fused bicyclic heterocycle derivatives as pesticides | DDT, CBR3, CYCS | HSD17B10 1027/4885NPC1 3180/4885RAB9A 374/4885 |
| US-20180116222-A1 | FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | DDT, CBR3, CYCS | HSD17B10 1027/4885NPC1 3180/4885RAB9A 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.